8-K: Apyx Medical Reports Q1 2026 Results, Raises FY2026 Revenue Guidance

Apyx Medical Corporation announced first quarter 2026 financial results, reporting $12.5 million in total revenue, a 32.4% increase year-over-year, and raised its full-year revenue guidance.

Summary

• Total revenue for the first quarter of 2026 reached $12.5 million, a significant increase from $9.4 million in the same period of 2025.
• Surgical Aesthetics segment revenue grew by 36.1% to $10.7 million, driven by AYON sales, international Renuvion generator sales, and increased handpiece volume.
• OEM revenue saw a 13.8% increase to $1.8 million.
• Net loss attributable to stockholders narrowed to $2.1 million ($0.05 per share) from $4.2 million ($0.10 per share) in Q1 2025.
• Adjusted EBITDA loss improved to $0.3 million from $2.4 million in the prior year period.
• Full-year 2026 total revenue guidance was raised to a range of $59.0 million to $60.0 million.
• Surgical Aesthetics revenue guidance for FY2026 was also increased to $54.0 million to $55.0 million.
• The company expects to yield cash through 2027 based on projections, including AYON platform uptake, working capital management, and cost controls.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth, improved profitability metrics, and an upward revision of future guidance, indicating solid execution and market reception.

Positives

• Total revenue increased by 32.4% to $12.5 million in Q1 2026.
• Surgical Aesthetics revenue grew by 36.1% to $10.7 million, indicating strong adoption of AYON and international Renuvion sales.
• International sales exceeded expectations, particularly in South Korea, a market with significant projected growth.
• Net loss attributable to stockholders decreased by 50% to $2.1 million.
• Adjusted EBITDA loss significantly improved, narrowing from $2.4 million to $0.3 million.
• Gross margin improved to 63.5% from 60.1% due to a favorable segment and product mix.
• Full-year 2026 total revenue guidance was raised to $59.0 million - $60.0 million.
• Renuvion won the 2026 NewBeauty award for Best Minimally Invasive Skin Tightener for the second consecutive year.

Negatives

• The company reported a net loss of $2.1 million for the quarter.
• OEM revenue is expected to decrease for the full year and continue this trend over time due to increased focus on Surgical Aesthetics.
• Tariffs began affecting the company in the second half of 2025, impacting gross margin.
• Operating expenses were essentially flat, with slight increases in salaries and SG&A, though offset by decreases in R&D and professional services.

Risks

• The regulatory environment, including obtaining approvals from the FDA and other governmental bodies, domestically and internationally.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions.
• Changes in general economic, business, or demographic conditions or trends.
• Changes in and effects of the geopolitical environment.
• Liabilities and costs from pending or threatened litigations, claims, disputes, or investigations.
• Potential impact of macroeconomic or geopolitical matters on financial performance.
• Risks described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and other SEC filings.

Future Outlook

The company has raised its full-year 2026 total revenue guidance to a range of $59.0 million to $60.0 million, up from previous guidance. Surgical Aesthetics revenue guidance was also increased to $54.0 million to $55.0 million. OEM revenue is expected to be approximately $5.0 million. Total operating expenses are expected to remain below $45.0 million for the year. Management projects the company will yield cash through 2027.

Management Comments

• "Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide."
• "During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea."
• "Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026."

Industry Context

StockSavvy.ai notes that Apyx Medical's strong Q1 performance and raised guidance align with positive trends in the surgical aesthetics market, particularly the growing demand for minimally invasive procedures and advanced body contouring systems like AYON. The company's international expansion, especially in markets like South Korea, reflects a broader industry trend of increasing aesthetic procedure adoption in emerging markets.

Comparison to Industry Standards

• The 32.4% year-over-year revenue growth in Q1 2026 for Apyx Medical significantly outpaces the typical growth rates seen in the broader medical device industry, which often ranges from single digits to low double digits.
• The improvement in Adjusted EBITDA loss from -$2.4 million to -$0.3 million demonstrates enhanced operational efficiency, a key metric investors scrutinize across the medical technology sector.
• The gross margin of 63.5% is competitive within the specialized surgical aesthetics segment, though direct comparisons are difficult without specific segment data from competitors like InMode or Candela Medical.
• The company's projected full-year revenue of $59.0 million to $60.0 million places it as a mid-tier player in the aesthetics market, with significant growth potential if current trends continue.

Legal Proceedings

• Potential liabilities and costs from pending or threatened litigations, claims, disputes, or investigations are a noted risk.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, narrowed losses, and raised future guidance, potentially leading to increased shareholder value.
• Employees: Continued growth and positive outlook may lead to job security and potential expansion opportunities.
• Customers: Access to innovative products like AYON and Renuvion, with potential for improved treatment outcomes.
• Suppliers: Increased demand for products may lead to sustained or increased business volume.

Next Steps

• Management to host a conference call on May 7, 2026, at 8:00 a.m. ET to discuss Q1 2026 results.
• Continued focus on commercial strategy execution and adoption of AYON in the U.S.
• Expansion of Renuvion sales internationally.
• Leveraging regulatory approval in South Korea for growth.

Key Dates

Recommendation

While the Q1 results are strong and guidance has been raised, the company still operates at a net loss. The improved financial metrics and positive outlook warrant a 'hold' recommendation, suggesting investors should monitor continued execution and path to profitability before considering a more aggressive stance.

Keywords

Apyx Medical, Renuvion, AYON Body Contouring System, Surgical Aesthetics, OEM, Q1 2026 Results, Revenue Guidance, Medical Devices